In this retrospective study we analyzed our experience with mucoepidermoid carcinoma (MEC) of the salivary glands and compared our results with those reported in the literature. A total of 42 patients were treated between January 1983 and December 2002 at the Department of Oral and Maxillofacial Surgery, Hanover Medical School. Thirty-three tumors were classified as low grade carcinomas, 9 tumors as high grade carcinomas. Tumor sites were the parotid gland in 11 cases, sublingual and submandibular gland in 6 cases, oral cavity and oropharynx in 22 cases and nasal cavity and maxillary sinus in 3 cases. There were 23 T1-, 6 T2-, 5 T3- and 8 T4-tumors with 35 N0-, 5 N1- and 2 N2-necks, all M0 at presentation. Resection remained incomplete for 9 patients. Six patients received postoperative radiation. Overall survival rates, overall local control rates and overall regional control rates at 5 and 10 years were 79.1% and 65.5%, 89.1% and 80.8%, 92.3% and 87.7%. None of our patients developed distant failure. Grade, stage and margin status significantly influenced prognosis. MEC is a rare tumor entity and should be treated in specialist centres within randomised prospective multicentric trials.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.oraloncology.2004.01.017 | DOI Listing |
Ear Nose Throat J
January 2025
Ear, Nose, and Throat Department, General Hospital of Athens "G. Gennimatas," Athens, Greece.
Genes (Basel)
December 2024
School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Salivary gland carcinomas encompass a broad group of malignant lesions characterized by varied prognoses. Stem cells have been associated with the potential for self-renewal and differentiation to various subpopulations, resulting in histopathological variability and diverse biological behavior, features that characterize salivary gland carcinomas. This study aims to provide a thorough systematic review of immunohistochemical studies regarding the expression and prognostic significance of stem cell markers between different malignant salivary gland tumors (MSGTs).
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Salivary gland malignancies are rare, accounting for less than 5% of head and neck cancers. Mucoepidermoid carcinoma (MEC) is the most common salivary gland tumour, predominantly found in the parotid gland. However, it has rarely been reported in the tongue.
View Article and Find Full Text PDFAppl Radiat Isot
January 2025
Department of Otolaryngology Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Purpose: Boron neutron capture therapy (BNCT) perform as a treatment option for locally advanced or recurrent unresectable head and neck cancers since June 2020 in Japan. The effect of BNCT on parotid carcinoma, which presents a variety of histologic types, remains unclear. The object of this study was to investigate the antitumor efficacy of BNCT against parotid gland carcinoma by focusing on LAT1, which is involved in the uptake of L-BPA, the boron compound used in BNCT.
View Article and Find Full Text PDFSLAS Discov
January 2025
Center of Excellence and Innovation for Oral Health and Healthy Longevity, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!